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Abstract
Background: Ovarian cryopreservation is one option for fertility preservation in patients with cancer. The danger of
reseeding malignancies could be eliminated by in vitro maturation of primordial follicles from the frozen-thawed tissue.
However, the development of this system is hindered by uncertainties regarding factors that activate primordial follicles.
Neuronal growth factors such as vasoactive intestinal peptide (VIP) play important roles in early mammalian folliculogenesis.
There are no data on the expression of VIP and its vasoactive intestinal peptide pituitary adenylate cyclase 1 and 2 receptors
(VPAC1-R and VPAC2-R) in human preantral follicles.
Methodology/Principal Findings: Tissue samples from 14 human fetal ovaries and 40 ovaries from girls/women were
prepared to test for the expression of VIP, VPAC1-R, and VPAC2-R on the protein (immunohistochemisty) and mRNA (reverse
transcription polymerase chain reaction) levels. Immunohistochemistry staining was mostly weak, especially in fetal
samples. The VIP protein was identified in oocytes and granulosa cells (GCs) in the fetal samples from 22 gestational weeks
(GW) onwards. In girls/women, VIP follicular staining (oocytes and GCs) was identified in 45% of samples. VPAC1-R protein
was identified in follicles in all fetal samples from 22GW onwards and in 63% of the samples from girls/women (GC staining
only in 40%). VPAC2-R protein was identified in follicles in 33% of fetal samples and 47% of the samples from girls/women.
The mRNA transcripts for VIP, VPAC1-R, and VPAC2-R were identified in ovarian extracts from fetuses and women.
Conclusions: VIP and its two receptors are expressed in human ovarian preantral follicles. However, their weak staining
suggests they have limited roles in early follicular growth. To elucidate if VIP activates human primordial follicles, it should
be added to the culture medium.
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Introduction
One option for fertility preservation in female patients with
cancer is cryopreservation of ovarian tissue containing primordial
follicles [1–3]. Studies reported that reimplantation of frozen-
thawed ovarian tissue from cancer patients resulted in livebirths [3].
However, the procedure carries a risk of transmitting malignancies
[2,4], which could be eliminated by in vitro maturation of primordial
follicles [4,5]. The development of a successful in vitro maturation
system is currently hindered by uncertainties regarding the factors
that promote primordial follicular development.
There is increasing evidence of the importance of neuronal
growth factors such as neurotrophins in ovarian function [6–11].
Neuronal growth factors are probably also involved in early
folliculogenesis, including activation of primordial follicles. One
such factor is the neuropeptide vasoactive intestinal peptide (VIP)
[12]. It is a 28-amino acid peptide derived from a 170-amino acid
precursor (PreProVIP), that was first isolated in 1970 from extracts
of porcine duodenum [13,14]. VIP is one of the major peptide
transmitters in the central and peripheral nervous system and has
a variety of biological actions including vasodilatation, relaxation
of gastrointestinal smooth muscle and release of hormones from
the pancreas and adenohypophysis [15]. Its activities are mediated
by two classes of G-protein-coupled receptors namely vasoac-
tive intestinal peptide pituitary adenylate cyclase 1 or 2 receptors
(VPAC1-R and VPAC2-R) [16]. The VIP receptors are charac-
terized by large, complex N-terminus domains that contain a high
concentration of cysteine residues. The first and second extracel-
lular loops also contain a high concentration of cysteine residues
which participate in disulfide bonds essential in maintaining
ligand-binding topology. Receptor function is coupled to adenylate
cyclase or phospholipase C or D activation [17].
There is limited information on the expression of VIP or its
receptors in mammalian preantral ovarian follicles. In experimen-
tal studies, VPAC1-R and VPAC2-R were detected in the ovaries
of sexually mature mice [18], and VIP was detected at the onset of
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expression with gestational age [15]. In vitro exposure of neonate
rat ovaries (containing either primordial follicles or follicles during
follicular assembly) to VIP increased levels of cytochrome P-450
aromatase (P-450arom) and mRNA transcripts of follicle stimu-
lating hormone (FSH) receptor [19]. Similarly, in goats, the pre-
sence of VIP improved preantral follicular survival and develop-
ment [12].
In humans, the expression of VIP and its receptors in preantral
follicles has not been investigated. The aim of the present study
was to determine the expression of VIP and its two receptors in
human ovarian cortical follicles from fetuses, girls, and women on
both the protein level, by immunohistochemistry (IMH) and the
messenger RNA (mRNA) level, by reverse transcription polymer-
ase chain reaction (RT-PCR). Indentifying the VIP system in
human primordial follicles will suggest possible VIP involvement
in their activation.
Results
IMH Detection of VIP, VPAC1-R and VPAC2-R Proteins
Table 1 summarizes the IMH findings for the expression of VIP
and its receptors in ovarian samples from fetuses, girls and women.
Positive red-brown staining for VIP, VPAC1-R and VPAC2-R
was detected in all the sections tested. In the oocyte, findings were
subclassified as nuclear staining and cytoplasmic staining. Positive
oocyte staining was described as either full (staining in the whole
cytoplasm) or partial (staining only in part of the cytoplasm). A
follicle with at least one red-brown granulosa cell (GC) was defined
as positively stained in its GCs. Negative staining was defined as an
absence of red-brown staining (only blue counterstaining).
The characteristic cellular localization of the VIP protein in
fetuses is represented in Figure 1A. Staining was weak. Follicular
staining was identified from 22 gestational weeks (GW) onwards.
Full positive staining in the cytoplasm with nuclear staining was
identified in all of these oocytes and in a portion of the GCs of
each follicle. The characteristic cellular localization of VIP in
girls/women is represented in Figure 1B. Follicular staining was
identified in 45% of the samples, in which oocyte cytoplasmic
staining was full in 70% and partial in 30% with nuclear staining;
a portion of the GCs of all these specimens stained positively. The
positive control stained positively (Figure 1C).
The characteristic cellular staining of the VPAC1-R protein in
fetuses was very weak, and therefore, no picture is presented.
Follicular staining was identified from 22 GW onwards. Full posi-
tive staining in the cytoplasm with nuclear staining was detected in
all oocytes and in the GCs. The characteristic cellular localization
of the staining for VPAC1-R in girls/women is represented in
Figure 2A. Follicular staining was identified in 63% of the samples,
in all of which oocyte cytoplasmic staining was full with nuclear
staining. Staining in GCs was identified in 40% of the specimens
and only in a portion of the GCs of each follicle.
The characteristic cellular localization of the VPAC2-R protein
in fetuses is represented in Figures 3A. Staining was weak.
Follicular staining was identified regardless of gestational age in
33% of the samples, in which oocyte cytoplasmic staining was full
with nuclear staining. Positive staining was identified in a portion
of the GC of each follicle. The characteristic cellular localization
for VPAC2-R in girls/women is represented in Figure 3B. Fol-
licular staining was identified in 47% of the samples, in which
oocyte cytoplasmic staining was full in 63% and partial in 37%
with nuclear staining in all. Positive staining was identified in a
portion of the GCs of each follicle.
A portion of the stroma cells in all the samples expressed the
proteins for VIP, VPAC1-R and VPAC2-R. There was no fur-
ther association of the results with ovarian source (fetus, girls and
women), fetal abnormalities, age, or follicular class. The negative
controls for all three proteins stained only with the blue hema-
toxylin counterstain (Figures 1D, Figure 1E, 2B, 3C and 3D).
Follicular Counts
In the samples from fetuses on IMH studies, 1584 follicles were
counted: 1456 (91.9%) primordial and 127 (8%) primary. In the
samples from girls/women, 952 follicles were counted: 767
(80.6%) primordial, 169 (17.8%) primary, 14 (1.5%) secondary
and 1 antral (0.1%).
RT-PCR Results
RT–PCR analysis was performed on eight samples from women
and eight samples from fetuses (Figure 4). All genes studied yielded
the expected fragments in all samples from both sources. Positive
findings were also obtained for the control dihydrofolate reductase
(DHFR) gene. None of the negative controls processed without
RT (RT-) yielded an amplification product.
Discussion
Our study is the first to provide information on the presence of
VIP, VPAC1-R and VPAC2-R in human cortical follicles from
fetuses, girls, and women. The VIP protein was identified in oocytes
and GCs in all samples from fetuses aged $22GW. In girls/women,
the VIP protein was identified in follicles in 45% of samples (full
cytoplasm staining in 70% of oocytes, partial 30%). The VPAC1-R
protein was identified in follicles of all fetal samples from 22GW
onwards and in 63% of the samples from girls/women (with GC
staining in 40%). The VPAC2-R protein was identified in follicles
in 33% of the fetal samples and 47% of the samples from girls/
women (full oocyte cytoplasmic staining in 63%, partial in 37%).
IMH staining was mostly weak, especially in the fetal samples. The
mRNA transcripts for VIP, VPAC1-R and VPAC2-R were
Table 1. Protein expression (IMH) of VIP, VPAC1-R and
VPAC2-R in human ovaries.
Source VIP VPAC1-R VPAC2-R
Fetus Weak Weak Weak
Oocyte + From 22GW + From 22GW +33%
Cytoplasm + Full from 22GW + Full from 22GW + Full
Nucleus + From 22GW + From 22GW +
GCs + From 22GW + From 22GW +
Stroma + All samples + All samples + All samples
Girls/Women Weak-Medium Weak Weak-Medium
Oocyte +45% +63% +47%
Cytoplasm Full (70%)/
Partial (30%)
+ Full Full (63%)/
Partial (37%)
Nucleus ++ +
GCs ++ 40% of stained + all stained
Stroma + All samples + All samples + All samples
Note: IMH=immunohistochemistry, GW=gestational weeks. Percentages
represent the proportion of the samples with follicular staining.
Staining intensities: +=positive staining; full/partial=full or partial cytoplasmic
staining.
doi:10.1371/journal.pone.0037015.t001
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women.
In general, we found a good correlation in expression of the
proteins for VIP and its receptors between the protein and the
mRNA levels. The weaker protein staining for VIP and its two
receptors in the fetal samples than in the samples from girls/women
maybeattributed toage-relateddevelopmentalchanges.Thisisalso
in line with the finding of fetal staining only from 22 GW onwards.
However, protein staining was weak in the fetal samples, while the
corresponding mRNA transcripts were easily identified. This
finding might be attributed to a higher sensitivity of RT-PCR to
low levels of mRNA transcripts relative to the sensitivity of IMH to
the relevant proteins [20]. In addition, our RT-PCR assay was
qualitative and not quantitative and, therefore, could not detect
changes in mRNA levels. Given that the protein staining for VIP
and/or its two receptors was mostly weak and not present in all
follicles from girls/women, it seems likely that the VIP system plays
a limited and as yet unknown role in early follicular growth in
humans.
Some information is available in the literature about VIP and its
two receptors in preantral follicles in other mammals [12,15,18,
19,21,22]. In a study of 22-day-old mice no mRNA transcripts for
VIP were identified, but VPAC1-R and VPAC2-R were detected in
the ovaries at both the protein level (Western blot) and mRNA level
(RT-PCR) [18]. The two receptors were identified in residual
ovarian tissue, and VPAC2-R also in GC. It is noteworthy that
VPAC1-R was downregulated by human chorionic gonadotrophin
[18]. In a study of bovine ovaries, VIP was detected from four and a
half to six months of gestation coinciding with the onset of follicular
development; its expression increased with gestational age [15]. VIP
immunoreactivity was limited to the ovarian cortex up to the age of
nine monthsofgestation, andthereafterwas found inthemedulla as
well around blood vessels and nonvascular smooth muscle cells, and
near preantral follicles. After birth, the number of VIP immuno-
Figure 1. IMH photographs of VIP protein expression. (A) Section of human ovary from a 22-GW-old fetus. Note the primordial follicles, weak
red-brown staining indicating VIP expression in oocytes (full cytoplasmic and nuclear staining), and weak staining in a portion of the GC and stroma
cells. Original magnification X400. (B) Section of human ovary from a 6-year-old girl. Note the primordial follicles with red-brown staining indicating
VIP protein expression in the oocyte (mainly cytoplasmic staining and nuclear staining), and in a portion of the GC and a portion of the stroma cells.
Original magnification X400. (C) Positive control for VIP protein expression of section of mouse brain. Note the red-brown staining in the sample.
Original magnification X400. (D) Negative control for the same ovarian section as in panel A. Note the primordial follicles with the overall blue
staining and the lack of red-brown staining. Original magnification X400. (E) Negative control for the same ovarian section as in panel B. Note the
primordial follicles with overall blue staining and the lack of red-brown staining. Original magnification X400.
doi:10.1371/journal.pone.0037015.g001
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and medulla [15]. The age-related changes in the bovine are
comparable with our findings of a weaker expression of the proteins
for VIP and its two receptors in human fetal ovaries (only from 22
GW onwards) than in ovaries from girls/women. Differences be-
tween our results in humans and those in mice [18] and cows [15]
canbe attributedto species differences. Moreover, unlike the bovine
study [15] we did not study the ovarian human medulla, as it was
removed from the cortex either during the operation itself or during
tissue preparation before cryopreservation. Indeed, a recent study
identified preantral follicles also in the human medulla [23], but we
were unaware of these findings at the time of tissue collection.
There seem to be complex interactions between VIP and FSH
at least in rodents. Therefore, VIP might be a regulator of FSH
function [19,21]. The addition of VIP to preantral follicles from
adult mice that were already under FSH induction caused a dose-
dependent inhibition of follicular growth, antrum formation, GC
proliferation, and estradiol production [21]. In the neonatal rat
ovary (containing mostly primordial follicles), VIP caused (within
eight hours of treatment) a dose-dependent increase in FSH re-
ceptor mRNA accompanied by the formation of functional recep-
tor molecules, as demonstrated by the ability of FSH to stimulate
the formation cyclic adenylate monophosphate [19]. At the same
time, VIP also increased aromatase activity prior to folliculogenesis
[22] and the steady state levels of P-450arom mRNA [19]. In the
goat, VIP improved preantral follicular survival and development
after in vitro culture and assisted in maintaining follicular
ultrastractural integrity on transmission electron microscopy study
[12].
The studies in mammals [12,15,18,19,21,22] and the present
study in humans, all suggest that VIP plays a role in early follicular
development. Although the precise function of VIP in primordial/
preantral follicles is still unclear, it seems to be species and age-
dependent (increases with age) and to involve interactions with
other factors. Some of the studies showed that VIP alone sti-
mulated the growth of preantral follicles [12,19,22], whereas its
synergism with FSH inhibited follicular growth [21]. In future
studies, to elucidate if VIP is involved in the activation of human
primordial follicles, it could be added to the culture medium
without any additional factor [12,19,21,22]. At the same time, the
limited staining of VIP and its two receptors in human preantral
follicles, suggests a limited and as yet unknown function of VIP in
early follicular development in humans. Therefore, further studies
of the association of other growth factors with the development of
human primordial follicles are needed.
Materials and Methods
Human Ovaries from Fetuses, Girls and Women
Ovarian samples were obtained from 14 human fetuses aged 21–
33 GW, following approved pregnancy terminations (performed
mostly because of fetal abnormalities) [8,10,11]. In addition, small
ovarian cortical biopsy samples were donated by 40 girls/women
aged 5–39 years or their parents. All had undergone ovarian
laparoscopies for either cryopreservation of ovarian tissue before
commencement of chemotherapy or for removal of ovarian cysts.
The Ethics Committee of Rabin Medical Center approved the
study, and every patient or minor’s parents signed an informed
consent form.
The samples were cut to uniform-size and fixed immediately.
The remaining sample material was frozen until RNA extraction
[8,10,11].
Figure 2. IMH photographs of VPAC1-R protein expression. (A) Section of human ovary from a 22-year-old woman. Note the primordial
follicles, with red-brown staining indicating VPAC1-R expression in the oocytes (full cytoplasmic staining and nuclear staining), and in a portion of the
GC and stroma cells. Original magnification X400. (B) Negative control for the same ovarian section as in panel A. Note the primordial follicle, overall
blue staining, and lack of red-brown staining. Original magnification X400.
doi:10.1371/journal.pone.0037015.g002
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Tissue slices were placed in cryogenic vials (Nalge Nunc Inter-
national, Roskilde, Denmark) with a solution of dimethylsulfoxide
(1.5 M) (Sigma, St. Louis, USA) [8,10,11]. Prior to freezing, the
samples were kept on ice for 30 minutes to reach equilibrium with
the solution. The specimens were then frozen in a programmable
freezer (Kryo 360-1/7, Planer Biomed, Sunbury on Thames, UK),
and immediately placed in liquid nitrogen. The slices were cryo-
stored until RNA extraction.
Histological Preparation
Our histological preparation method has been described in
detail elsewhere [8,10,11]. The fixed specimens were dehydrated
in a graded series of ethanol and toluene followed by paraffin
embedding and sectioning. Unstained sections were placed on
OptiPlus positive-charged microscope slides (BioGenex Laborato-
ries, San Ramon, CA, USA) for IMH.
IMH for VIP, VPAC1-R and VPAC2-R
Our IMH methods have been described in detail elsewhere
[8,10,11]. In brief, two sections per sample were utilized for the
identification of the VIP, VPAC1-R and VPAC2-R proteins. To
enhance antigen retrieval, all slides were microwaved with citrate
buffer at pH 6.0 (CheMate buffer, DAKOCytomation, Glostrup,
Denmark), and to block endogenous peroxidase activity, the slides
were quenched in 3% hydrogen peroxide (H2O2, Vitamed,
Binyamina, Israel). A mouse brain sample served as a positive
control for VIP (according to instructions from Santa Cruz
Figure 3. IMH photographs of VPAC2-R protein expression. (A) Section of a human ovary from the same fetus as in Figure 1 (A) and (D). Note
the red-brown staining indicating VPAC2-R expression in the oocytes (full weak cytoplasmic staining with nuclear staining), in a portion of the GC and
stroma cells. Original magnification X400. (B) Section of human ovary from the same woman as in Figure 2 (A) and (B). Note the secondary follicle (full
cytoplasmic staining with nuclear staining), with red-brown staining in the GC and stroma cells. Original magnification X400. (C) Negative control for
the same ovarian section as in panel A. Note the primordial follicles with overall blue staining and lack of red-brown staining. Original magnification
X400. (D) Negative control for the same ovarian section as in panel B. Note the primordial follicles with overall blue staining and lack of red-brown
staining. Original magnification X400.
doi:10.1371/journal.pone.0037015.g003
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a mouse that was scarified (with efforts to minimize suffering) for a
previous study according to a protocol and recommendations ap-
proved by the Committee on the Ethics of Animal Experiments at
Rabin Medical Center [24]. Unfortunately, there are no com-
mercially available positive controls for VPAC1-R and VPAC2-R.
Primary antibodies were goat polyclonal antibodies against VIP,
VPAC1-R and VPAC2-R, which are reported to be suitable for
IMH according to the manufacturer, (Santa Cruz Biotechnology,
catalogue numbers: sc-21041, sc-31633 and sc-15961, respective-
ly). The samples were incubated with the primary antibodies
diluted 1/10 and 1/30. Negative control solutions were prepared
for VIP, VPAC1-R and VPAC2-R by absorption of their primary
antibodies with their corresponding blocking peptide (Santa Cruz
Biotechnology, catalogue numbers: sc-21041P, sc-31633P and
sc-15961P, respectively). Red–brown 3-amino-9-ethylcarbazole
(Zymed Laboratories Inc., San Francisco, CA, USA) staining
indicated the presence of antigen, with blue Mayer’s hematoxylin
(Pioneer Research Chemicals Ltd., Colchester Essex, UK)
counterstaining.
Follicular Counts
The number of follicles in every IMH stained section was
counted with an image analyzer (analySIS, Soft Imaging System,
Digital Solutions for Imaging and Microscopy, System GmbH,
Munster, Germany) [8,10,11]. The follicles were classified as fol-
lows [25]: primordial (with a single flat layer of GC surrounding the
oocyte), primary (with a single cuboidal GC layer surrounding the
oocyte), secondary (with at least two GC layers and a theca layer
surrounding the oocyte); and antral (with a fluid-filled cavity
within the GC). Follicles preceding the antral stage (primordial,
primary and secondary) were collectively termed preantral.
RT-PCR
A TRIzol Reagent protocol (Pioneer Research Chemicals) was
used for mRNA extraction from frozen ovarian samples, as
described in detail elsewhere [8, 10, 11). The concentration of
each sample was measured using a spectrophotometer (Cary UV
100; Varian, Mulgrave, Australia), and samples were stored at
280uC until RT-PCR was performed.
FrozentotalRNAsamplesfrom eight adultandeight fetalovaries
were centrifuged at 13,000 g for 30 min at 4uC. After the
supernatant was completely removed, the pellets containing RNA
were resuspended in 50 ml RNase-free water. The concentration of
eachsample was measuredby spectrophotometer (NanoDrop 2000,
Thermo Scientific, Wilmington, DF, USA). The samples were
aliquoted, 0.5 mg RNA per PCR tube, and stored at –80uC. A total
of 0.5 mg RNA was used for cDNA synthesis in the presence (RT+)
or absence (RT–) of reverse transcriptase (Moloney murine
leukemia virus, M-MLV RT) according to the manufacturer’s in-
structions (Invitrogen, catalogue number 280250, Life Technolo-
gies, Grand Isler, NY, USA).
The cDNA amplification primers for VIP, VPAC1-R, and
VPAC2-R were designed to span at least one intron so as to identify
genomic DNA contamination. A single-round PCR approach was
used to detect transcripts of VIP (accession number NM_194435.1),
VPAC1-R (accession number NM_004624.3), and VPAC2-R
(accession number NM_003382.4). To detect VIP, the forward
primer (59-tcaaacgtcactcagatgcag-39) and reverse primer (59-tcttc-
tggaaagtcgggaga-39) were designed in exon 4 and exon 5. The
expected PCR product size was 134 base pairs (bp). To detect
VPAC1-R, the forward primer (59-ccggacaattttaagcctga-39)a n d
reverse primer (59-accattgaggaagcagtagagg-39) were designed in
exon 11 and exon 12. The expected PCR product size was 97 bp.
To detect VPAC2-R, the forward primer (59-tgtactgagactggtcgttgc-
39) and reverse primer (59-tgggatacaaacgaccacag-39) were designed
in exon 4 and exon 5. The expected PCR product size was 155 bp.
Figure 4. Representative RT-PCR gel illustrating expression of the VIP, VPAC1-R and VPAC2-R genes in fetal and adult ovaries. (A)
VIP gene (134 base pairs), (B) VPAC1-R gene (97 base pairs), (C) VPAC2-R gene (155 base pairs), (D) DHFR gene as positive control (231base pairs).
Sample 1: Ovary from a 21-year-old woman, Sample 2: Ovary from a 29-year-old woman, Sample 3: Ovary from a 39-year-old woman, Sample 4: Ovary
from a 21-GW-old fetus, Sample 5: Ovary from a 23-GW-old fetus, Sample 6: Ovary from a 25-GW-old fetus, Sample 7: Ovary from a 27-GW-old fetus.
M: Marker (100 base pair DNA ladder, QIAGEN), +: RT presence, -: RT absence.
doi:10.1371/journal.pone.0037015.g004
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control for the RT-PCR. The forward primer (59-ggttgtggtcattctctg-
gaa-39) and reverse primer (59-ctcgcctgcacaaatgg-39) were designed
in exon 5 and exon 6. The expected PCR product size was 231 bp.
The annealing temperature for all four PCR reactions was 53uC
and for all four the cycle number was 40.
The total 20 ml PCR reaction contained 2 ml of reverse-
transcribed cDNA, 10 mlo f2 6 Master Mix (Fast Cycling PCR
Kit, QIAGEN, Ontario, Canada), and 0.2 mM of each primer.
PCR was carried out according to the manufacturer’s instruction
(QIAGEN, catalogue number 203741). The amplified product was
subjected to 4% agarose gel electrophoresis, using a 100 base-pair
ladder as a reference (100 bp Ladder, QIAGEN) for fragment size,
and stained with ethidium bromide.
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